Compare ResMed Inc. (RMD) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while State Street SPDR S&P Homebuilders ETF trades at $94.83 (market cap $1.49B). The key difference: ResMed Inc. is far larger — about 21.4× State Street SPDR S&P Homebuilders ETF's market cap, and ResMed Inc. pays a 1.16% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| RMD | XHB | |
|---|---|---|
Market Cap | $31.89B | $1.49B |
Volume | 618,314 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $277.88 | $121.36 |
52-Week Low | $182.82 | $94.86 |
Typical Hold Time | 51 Days | 33 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.99, showing minimal daily change. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but shows potential from recent housing policy support and institutional interest.
The outlook for XHB is mixed, balancing sector challenges like rising rates against catalysts such as new housing legislation. Investment opportunity hinges on a housing market rebound, while risks include economic sensitivity and rate volatility. Investor sentiment is cautious but attentive to policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
